No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
ASX Small-Cap Stocks to Watch
Amplia Therapeutics Gets US FDA Nod for Changes to Study
Amplia Therapeutics Completes Early Recruitment for Pancreatic Cancer Trial
Amplia Therapeutics Ltd: App 4D and Financial Report Half Year ended 30 Sep 2024
Amplia Therapeutics: FDA Granted Fast-Track Designation to Amplia's Lead Drug Narmafotinib in Advanced Pancreatic Cancer >ATX.AU
FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER